130 related articles for article (PubMed ID: 37814985)
1.
Zhang Z; Wang H; Jin Y; Zhou J; Chu C; Tang F; Zou L; Zou Q
Biomark Med; 2023 Jun; 17(12):553-562. PubMed ID: 37814985
[No Abstract] [Full Text] [Related]
2. CDH2/N-cadherin and early diagnosis of invasion in patients with ductal carcinoma in situ.
Guvakova MA; Prabakaran I; Wu Z; Hoffman DI; Huang Y; Tchou J; Zhang PJ
Breast Cancer Res Treat; 2020 Sep; 183(2):333-346. PubMed ID: 32683564
[TBL] [Abstract][Full Text] [Related]
3. Expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in ductal carcinoma in situ (DCIS) and DCIS with microinvasion.
Wan ZB; Gao HY; Wei L; Zhang AQ; Zhang JY; Wang Y; Wang DD; Zhang Y
Medicine (Baltimore); 2018 Nov; 97(44):e13055. PubMed ID: 30383678
[TBL] [Abstract][Full Text] [Related]
4. Biologic behavior and long-term outcomes of breast ductal carcinoma in situ with microinvasion.
Fang Y; Wu J; Wang W; Fei X; Zong Y; Chen X; Huang O; He J; Chen W; Li Y; Shen K; Zhu L
Oncotarget; 2016 Sep; 7(39):64182-64190. PubMed ID: 27577080
[TBL] [Abstract][Full Text] [Related]
5. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
[TBL] [Abstract][Full Text] [Related]
6. PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma.
Sakr RA; Weigelt B; Chandarlapaty S; Andrade VP; Guerini-Rocco E; Giri D; Ng CK; Cowell CF; Rosen N; Reis-Filho JS; King TA
Clin Cancer Res; 2014 May; 20(9):2326-37. PubMed ID: 24634376
[TBL] [Abstract][Full Text] [Related]
7. Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS.
Visser LL; Elshof LE; Van de Vijver K; Groen EJ; Almekinders MM; Sanders J; Bierman C; Peters D; Hofland I; Broeks A; van Leeuwen FE; Rutgers EJT; Schmidt MK; Schaapveld M; Lips EH; Wesseling J
Am J Surg Pathol; 2019 Nov; 43(11):1574-1582. PubMed ID: 31206365
[TBL] [Abstract][Full Text] [Related]
8. Clinic-Pathological Features of Breast Ductal Carcinoma
Zheng J; Zhou T; Li F; Shi J; Zhang L
Cancer Invest; 2020 Feb; 38(2):113-121. PubMed ID: 31939679
[No Abstract] [Full Text] [Related]
9. Different distribution of breast ductal carcinoma in situ, ductal carcinoma in situ with microinvasion, and invasion breast cancer.
Zhang W; Gao EL; Zhou YL; Zhai Q; Zou ZY; Guo GL; Chen GR; Zheng HM; Huang GL; Zhang XH
World J Surg Oncol; 2012 Dec; 10():262. PubMed ID: 23216911
[TBL] [Abstract][Full Text] [Related]
10. The significance of HER-2/neu receptor positivity and immunophenotype in ductal carcinoma in situ with early invasive disease.
Harada S; Mick R; Roses RE; Graves H; Niu H; Sharma A; Schueller JE; Nisenbaum H; Czerniecki BJ; Zhang PJ
J Surg Oncol; 2011 Oct; 104(5):458-65. PubMed ID: 21557226
[TBL] [Abstract][Full Text] [Related]
11. Comparison of nuclear grade and immunohistochemical features in situ and invasive components of ductal carcinoma of breast.
Aguiar FN; Mendes HN; Bacchi CE; Carvalho FM
Rev Bras Ginecol Obstet; 2013 Mar; 35(3):97-102. PubMed ID: 23538467
[TBL] [Abstract][Full Text] [Related]
12. Identification of biomarkers in ductal carcinoma in situ of the breast with microinvasion.
Okumura Y; Yamamoto Y; Zhang Z; Toyama T; Kawasoe T; Ibusuki M; Honda Y; Iyama K; Yamashita H; Iwase H
BMC Cancer; 2008 Oct; 8():287. PubMed ID: 18837981
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological Follow-up of Breast DCIS Diagnosed on Biopsies: A Single Institutional Study of 575 Patients.
Yan M; Bomeisl P; Gilmore H; Harbhajanka A
Int J Surg Pathol; 2021 Dec; 29(8):836-843. PubMed ID: 33890815
[TBL] [Abstract][Full Text] [Related]
14. Breast ductal Carcinoma in situ associated with microinvasion induces immunological response and predicts ipsilateral invasive recurrence.
Chen XY; Thike AA; Koh VCY; Nasir NDM; Bay BH; Tan PH
Virchows Arch; 2021 Apr; 478(4):679-686. PubMed ID: 33140128
[TBL] [Abstract][Full Text] [Related]
15. Ductal carcinoma in situ and ductal carcinoma in situ with microinvasion: correlation of FDG uptake with histological and biological prognostic factors.
Seo YY; Yoo IR; Park SY; Oh JK; Kim SH; Sohn HS
Breast Cancer; 2017 May; 24(3):353-361. PubMed ID: 27312540
[TBL] [Abstract][Full Text] [Related]
16. Serum autoantibody signature of ductal carcinoma in situ progression to invasive breast cancer.
Mangé A; Lacombe J; Bascoul-Mollevi C; Jarlier M; Lamy PJ; Rouanet P; Maudelonde T; Solassol J
Clin Cancer Res; 2012 Apr; 18(7):1992-2000. PubMed ID: 22322670
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics of breast ductal carcinoma in situ with microinvasion: a narrative review.
Zheng J; Yu J; Zhou T
J Int Med Res; 2020 Nov; 48(11):300060520969304. PubMed ID: 33179556
[TBL] [Abstract][Full Text] [Related]
18. Breast ductal carcinoma in situ with microinvasion: a definition supported by a long-term study of 1248 serially sectioned ductal carcinomas.
de Mascarel I; MacGrogan G; Mathoulin-Pélissier S; Soubeyran I; Picot V; Coindre JM
Cancer; 2002 Apr; 94(8):2134-42. PubMed ID: 12001109
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and behaviour of screen-detected ductal carcinoma in situ of the breast: comparison with symptomatic patients.
Koh VC; Lim JC; Thike AA; Cheok PY; Thu MM; Tan VK; Tan BK; Ong KW; Ho GH; Tan WJ; Tan Y; Salahuddin AS; Busmanis I; Chong AP; Iqbal J; Thilagaratnam S; Wong JS; Tan PH
Breast Cancer Res Treat; 2015 Jul; 152(2):293-304. PubMed ID: 26077641
[TBL] [Abstract][Full Text] [Related]
20. The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma in situ.
Toss MS; Miligy IM; Haj-Ahmad R; Gorringe KL; AlKawaz A; Mittal K; Ellis IO; Green AR; Rakha EA
Histopathology; 2019 Jun; 74(7):1025-1035. PubMed ID: 30725481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
